New anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™

Signum presented new anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™  at the International Investigative Dermatology Conference March 16-19 in Orlando, Florida. This conference for investigative dermatology has been running since 1985 to bring together all the minds within the dermatological industry to explore new trends and practices.

Here is the team with our poster for SIG-1273 that we worked on with Princeton University and Nerium international.


Signum's novel new molecular entities hold Significant pharmaceutical potential

We presented at this years Society of Investigative Dermatology Conference held in Portland, Oregon. The annual meeting covers not only basic science, but also emergent clinical and translational findings. The volume of Skin Cancer research has grown to nearly 200 presentations each year, along with extensive coverage of promising avenues of investigation, and novel therapies for Atopic Dermatitis and Psoriasis.

Our presentations focused on two therapeutic areas: Acne and Atopic Dermatitis.

Here are our poster presentations from this years SID Conference.

2017 SID Acne Poster: SIG-1459 and SIG*1460 anti-acne phytyl-cysteine compounds

2017 SID Atopic Dermatitis Poster: SIG-1451: A topical anti-inflammatory new molecular entity for atopic dermatitis (AD)


Signum Attending BIO International Convention on June 18-22, 2017

Signum Biosciences, INC. will be attending this years BIO International Convention in San Diego, California.


Visit us at BOOTH #5607

BIO International Convention is BIOTECHNOLOGY INDUSTRY ORGANIZATION which will cover the topics of Life Science, Biology, Biosciences, Drug Discovery, Genomics, Bioengineering, Cell Therapy, Pharma Industry and Biomanufacturing .



Signum Biosciences Receives $3.0M Phase IIB SBIR Grant for the Development of SIG1451, A Novel Atopic Dermatitis Therapeutic

Signum Biosciences, Inc. announces today that the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a Small Business Innovation Research (SBIR) Phase IIB grant totaling $3.0 million over 3 years for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis (AD).  

Utilizing the funding provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) via the preceding Phase II grant, Signum identified SIG1451 from its isoprenylcysteine (IPC) technology platform as its lead drug candidate for AD. This Phase IIB funding will be used to take SIG1451 through IND-enabling safety/toxicology studies and into the clinic, where Post-IND clinical, chemistry and formulation work will also be performed.

Dr. Eduardo Pérez, CSO stated, “Over the past decade we have built a robust medicinal chemistry and R&D team to mine our IPC library for new therapeutics. Building on the experience and momentum provided by SIG990/DMT210, we believe SIG1451 will provide an important additional, and potentially better, therapeutic option for those suffering from AD.” 

Full Press Release

SIG-990 aka ( DMT210) has entered into a Phase 2 Acne Rosacea Study conducted by our Dermata Therapeutics, LLC

Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the first patient with its lead compound DMT210, in a Phase 2 acne rosacea study. DMT210, (formerly Signum's SIG-990 molecule) is a topical gel specifically developed to downregulate the proinflammatory cytokines in the skin responsible for the inflammation and redness seen in acne rosacea.   Full Press Release

SIG-1191: an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes

Isoprenylcysteine (IPC) small molecules were discovered as signal transduction modulating compounds ~25 years ago. More recently, IPC molecules have demonstrated antioxidant and anti-inflammatory properties in a variety of dermal cells as well as antimicrobial activity, representing a novel class of compounds to ameliorate skin conditions and disease. Here, we demonstrate a new IPC compound, N-acetylglutaminoyl-S-farnesyl-l-cysteine (SIG-1191), which inhibits UVB-induced inflammation blocking pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production. To investigate further the previously reported hydrating potential of IPC compounds, SIG-1191 was tested for its ability to modulate aquaporin expression. Specifically, aquaporin 3 (AQP3) the most abundant aquaporin found in skin has been reported to play a key role in skin hydration, elasticity and barrier repair. Results show here for the first time that SIG-1191 increases AQP3 expression in both cultured normal human epidermal keratinocytes as well as when applied topically in a three-dimensional (3D) reconstructed human skin equivalent. Additionally, SIG-1191 dose dependently increased AQP3 protein levels, as determined by specific antibody staining, in the epidermis of the 3D skin equivalents. To begin to elucidate which signaling pathways SIG-1191 may be modulating to increase AQP3 levels, we used several pharmacological pathway inhibitors and determined that AQP3 expression is mediated by the Mitogen-activated protein kinase/Extracellular signal-regulated kinase kinase (MEK) pathway. Altogether, these data suggest SIG-1191 represents a new IPC derivative with anti-inflammatory activity that may also promote increased skin hydration based on its ability to increase AQP3 levels.

Here is the link to the full article. SIG-1191): an anti-inflammatory molecule that increases the expression of the aquaglyceroporin, aquaporin-3, in human keratinocytes